Dataset for "Molnupiravir inhibits Bourbon virus infection and disease-associated pathology in mice"
Description
Bourbon virus (BRBV) is an emerging tick-borne pathogen that causes severe, often fatal illness marked by cytopenia and thrombocytopenia. With no approved therapies or vaccines, treatment options remain limited. Using a preclinical mouse model, we evaluated molnupiravir, a broad-spectrum antiviral approved in the U.S. Molnupiravir reduced viral replication in cells and tissues, improved survival, and alleviated disease signs. These results highlight its potential as a therapeutic candidate for BRBV infection.
Files
Steps to reproduce
In this study, we used a preclinical lethal mouse model and cell culture assays to evaluate molnupiravir, a broad-spectrum antiviral approved in the U.S. Treatment significantly reduced viral replication in vitro and in vivo, improved survival, and suppressed clinical signs. For experimental details, please refer to the Methods section of the preprint article (https://doi.org/10.1101/2025.04.21.649883).
Institutions
- Washington University in St. Louis
Categories
Funders
Additional Metadata for Digital Commons Data@Becker
| Keywords | Bourbon Virus, Thogoto Virus, Dhori Virus, Molnupiravir, Antiviral, Tick-borne Disease, Pathology, Cytopenia, Pre-clinical Model |